Analysts matchmaking for Wockhardt although it says it is not for sale

Wockhardt's headquarters in Mumbai, India--Courtesy of Wockhardt

Executives at India's Wockhardt insist the troubled generics maker is not for sale--nada, no way. But that has not stopped analysts from discussing matchmaking, especially since execs at India's Lupin acknowledged recently that they analyzed whether buying Wockhardt would make sense. The analysts are suggesting some of the usual suspects: Teva Pharmaceutical Industries ($TEVA), Actavis ($ACT) and Mylan ($MYL). While Wockhardt has two of its plants banned by the FDA, analysts tell Bloomberg the right buyer might want the company just to get access to its extensive business in India, one of the faster growing global markets. Report | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.